These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3108351)

  • 1. Pathophysiology and biochemical mechanisms involved in MPTP-induced parkinsonism.
    Poirier J
    J Am Geriatr Soc; 1987 Jul; 35(7):660-8. PubMed ID: 3108351
    [No Abstract]   [Full Text] [Related]  

  • 2. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Singer TP; Castagnoli N; Ramsay RR; Trevor AJ
    J Neurochem; 1987 Jul; 49(1):1-8. PubMed ID: 3495634
    [No Abstract]   [Full Text] [Related]  

  • 3. The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and structurally related compounds.
    Markey SP; Schmuff NR
    Med Res Rev; 1986; 6(4):389-429. PubMed ID: 3534484
    [No Abstract]   [Full Text] [Related]  

  • 4. Astrocytes as a primary locus for the conversion MPTP into MPP+.
    Brooks WJ; Jarvis MF; Wagner GC
    J Neural Transm; 1989; 76(1):1-12. PubMed ID: 2785159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.
    Kopin IJ
    Adv Neurol; 1987; 45():137-44. PubMed ID: 3493621
    [No Abstract]   [Full Text] [Related]  

  • 6. Pargyline prevents MPTP-induced parkinsonism in primates.
    Langston JW; Irwin I; Langston EB; Forno LS
    Science; 1984 Sep; 225(4669):1480-2. PubMed ID: 6332378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+.
    Nakamura S; Vincent SR
    Neurosci Lett; 1986 Apr; 65(3):321-5. PubMed ID: 3487052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin.
    D'Amato RJ; Lipman ZP; Snyder SH
    Science; 1986 Feb; 231(4741):987-9. PubMed ID: 3080808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine oxidase B(MAO-B) is the major catalyst for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation in human brain and other tissues.
    Glover V; Gibb C; Sandler M
    Neurosci Lett; 1986 Feb; 64(2):216-20. PubMed ID: 3083305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MPTP toxicity: implications for research in Parkinson's disease.
    Kopin IJ; Markey SP
    Annu Rev Neurosci; 1988; 11():81-96. PubMed ID: 3129982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction of 1-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site.
    Russ H; Pindur U; Przuntek H
    J Neural Transm; 1986; 65(3-4):157-66. PubMed ID: 3011983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Barbeau A; Dallaire L; Buu NT; Veilleux F; Boyer H; de Lanney LE; Irwin I; Langston EB; Langston JW
    Life Sci; 1985 Mar; 36(11):1125-34. PubMed ID: 3871891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs.
    Youngster SK; Nicklas WJ; Heikkila RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):829-35. PubMed ID: 2786565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Sayre LM
    Toxicol Lett; 1989 Aug; 48(2):121-49. PubMed ID: 2672418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway.
    Bradbury AJ; Costall B; Domeney AM; Jenner P; Kelly ME; Marsden CD; Naylor RJ
    Nature; 1986 Jan 2-8; 319(6048):56-7. PubMed ID: 3484542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.
    Kindt MV; Youngster SK; Sonsalla PK; Duvoisin RC; Heikkila RE
    Eur J Pharmacol; 1988 Feb; 146(2-3):313-8. PubMed ID: 3131149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPTP-induced parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology.
    Schultz W
    Gen Pharmacol; 1988; 19(2):153-61. PubMed ID: 3127268
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioactivation of MPTP: reactive metabolites and possible biochemical sequelae.
    Trevor AJ; Castagnoli N; Caldera P; Ramsay RR; Singer TP
    Life Sci; 1987 Feb; 40(8):713-9. PubMed ID: 3492651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture.
    Snyder SH; D'Amato RJ
    Neurology; 1986 Feb; 36(2):250-8. PubMed ID: 3080696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain enzyme is the target of drug toxin.
    Lewin R
    Science; 1984 Sep; 225(4669):1460-2. PubMed ID: 6433484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.